| Literature DB >> 24699114 |
Xiang-Rong Tian1, Hai-Feng Tang2, Jun-Tao Feng3, Yu-Shan Li4, Hou-Wen Lin5, Xiao-Pei Fan6, Xing Zhang7.
Abstract
Five new ceramides, neritinaceramides A (1), B (2), C (3), D (4) and E (5), together with six known ceramides (6-11), two known alkyl glycerylethers (12 and 13) and a known nucleoside (14), were isolated from marine bryozoan Bugula neritina, which inhabits the South China Sea. The structures of the new compounds were elucidated as (2S,3R,3'S,4E,8E,10E)-2-(hexadecanoylamino)-4,8,10-octadecatriene-l,3,3'-triol (1), (2S,3R,2'R,4E,8E,10E)-2-(hexadecanoylamino)-4,8,10-octadecatriene-l,3,2'-triol (2), (2S,3R,2'R,4E,8E,10E)-2-(octadecanoylamino)-4,8,10-octadecatriene-l,3,2'-triol (3), (2S,3R,3'S,4E,8E)-2-(hexadecanoylamino)-4,8-octadecadiene-l,3,3'-triol (4) and (2S,3R,3'S,4E)-2-(hexadecanoylamino)-4-octadecene-l,3,3'-triol (5) on the basis of extensive spectral analysis and chemical evidences. The characteristic C-3'S hydroxyl group in the fatty acid moiety in compounds 1, 4 and 5, was a novel structural feature of ceramides. The rare 4E,8E,10E-triene structure in the sphingoid base of compounds 1-3, was found from marine bryozoans for the first time. The new ceramides 1-5 were evaluated for their cytotoxicity against HepG2, NCI-H460 and SGC7901 tumor cell lines, and all of them exhibited selective cytotoxicity against HepG2 and SGC7901 cells with a range of IC50 values from 47.3 μM to 58.1 μM. These chemical and cytotoxic studies on the new neritinaceramides A-E (1-5) added to the chemical diversity of B. neritina and expanded our knowledge of the chemical modifications and biological activity of ceramides.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24699114 PMCID: PMC4012440 DOI: 10.3390/md12041987
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Chemical structures of compounds 1–14 from the marine bryozoan Bugula neritina.
1H and 13C-NMR data of compounds 1 and 2 (500MHz for 1H-NMR, 125MHz for 13C-NMR) a.
| No. | 1 | 2 | |||
|---|---|---|---|---|---|
| 1 | 62.0 ( | 3.72 (1H, | 62.0 ( | 61.9 ( | 4.22 (1H, |
| 2 | 54.4 ( | 3.92 (1H, | 54.4 ( | 56.1 ( | 4.67 (1H, |
| 3 | 74.2 ( | 4.31 (1H, | 74.2 ( | 73.0 ( | 4.83 (1H, |
| 4 | 129.3 ( | 5.54 (1H, | 129.1 ( | 131.4 ( | 6.13 (1H, |
| 5 | 133.2 ( | 5.77 (1H, | 133.3 ( | 132.6 ( | 6.05 (1H, |
| 6 | 31.9 ( | 2.16 (2H, | 31.9 ( | 32.7 ( | 2.18 (1H, |
| 7 | 32.1 ( | 2.04 (2H, | 32.1 ( | 32.9 ( | 2.04 (1H, |
| 8 | 133.3 ( | 5.59 (1H, | 133.5 ( | 132.8 ( | 5.64 (1H, |
| 9 | 130.0 ( | 5.99 (1H, | 130.0 ( | 131.0 ( | 6.11 (1H, |
| 10 | 131.2 ( | 6.00 (1H, | 131.2 ( | 131.6 ( | 5.65 (1H, |
| 11 | 130.7 ( | 5.52 (1H, | 130.7 ( | 131.5 ( | 5.99 (1H, |
| 12 | 32.1 ( | 2.16 (2H, | 32.1 ( | 32.7 ( | 2.18 (2H, |
| 13 | 32.6 ( | 2.04 (2H, | 32.6 ( | 32.1 ( | 1.23 (2H, |
| 14 | 29.4 ( | 1.36 (2H, | 29.4 ( | 29.4 ( | 1.33 (2H, |
| 15 | 29.2 ( | 1.36 (2H, | 29.2 ( | 29.3 ( | 1.33 (2H, |
| 16 | 31.9 ( | 1.26 (2H, | 31.9 ( | 32.1 ( | 1.23 (2H, |
| 17 | 22.7 ( | 1.26 (2H, | 22.7 ( | 22.9 ( | 1.23 (2H, |
| 18 | 14.1 ( | 0.88 (3H, | 14.1 ( | 14.2 ( | 0.84 (3H, |
| 1′ | 173.0 ( | - | 175.0 ( | 175.4 ( | - |
| 2′ | 43.1 ( | a 2.30 (1H, | 72.4 ( | 72.5 ( | 4.59 (1H, |
| 3′ | 68.9 ( | 4.00 (1H, | 34.8 ( | 35.8 ( | 2.22 (1H, |
| 4′ | 37.1 ( | a 1.43 (1H, | 31.8 ( | 32.0 ( | 1.23 (2H, |
| 5′ | 25.6 ( | 1.37 (2H, | 25.1 ( | 25.9 ( | 1.64 (2H, |
| 6′~13′ | 29.2–29.7 ( | 1.26 (16H, | 29.2–29.7 ( | 29.3–30.0 ( | 1.23 (16H, |
| 14′ | 31.9 ( | 1.26 (2H, | 31.9 ( | 32.1 ( | 1.23 (2H, |
| 15′ | 22.7 ( | 1.26 (2H, | 22.7 ( | 22.9 ( | 1.23 (2H, |
| 16′ | 14.1 ( | 0.88 (3H, | 14.1 ( | 14.2 ( | 0.84 (3H, |
| NH | - | 6.65 (1H, | - | - | 8.34 (1H, |
a Assignments aided by the DEPT, COSY, HSQC, HMBC, and NOESY experiments; b data were obtained in CDCl3; c data were obtained in C5D5N; d overlapped with other signals.
Figure 2Key 1H–1H COSY and HMBC correlations (A), together with negative ESI-MS fragments (B) of compound 1.
Figure 3Methanolysis of compound 1.
Figure 4Key 1H-1H COSY and HMBC correlations (A), together with ESI-MS fragments (B) of compound 2 (a positive fragment ions; b negative fragment ions).
1H and 13C-NMR data of compounds 3–5 (CDCl3, 500MHz for 1H-NMR, 125MHz for 13C-NMR) a.
| No. | 3 | 4 | 5 | |||
|---|---|---|---|---|---|---|
| 1 | 62.2 ( | 3.75 (1H, | 61.8 ( | 3.71 (1H, | 61.9 (t) | 3.74 (1H, |
| 2 | 54.4 ( | 3.91 (1H, | 54.5 ( | 3.92 (1H, | 56.1 ( | 3.93 (1H, |
| 3 | 74.2 ( | 4.28 (1H, | 74.1 ( | 4.28 (1H, | 74.1 ( | 4.28 (1H, |
| 4 | 129.2 ( | 5.54 (1H, | 128.9 ( | 5.51 (1H, | 128.6 ( | 5.53 (1H, |
| 5 | 133.3 ( | 5.77 (1H, | 133.5 ( | 5.77 (1H, | 134.3 ( | 5.65 (1H, |
| 6 | 31.9 ( | 2.16 (2H, | 32.6 ( | 1.96 (2H, | 32.3 ( | 2.05 (2H, |
| 7 | 32.1 ( | 2.04 (2H, | 32.4 ( | 2.11 (2H, | 29.2–29.7 ( | 1.26 (2H, |
| 8 | 133.5 ( | 5.59 (1H, | 131.3 ( | 5.41 (1H, | 29.2–29.7 ( | 1.26 (2H, |
| 9 | 130.0 ( | 5.98 (1H, | 129.0 ( | 5.38 (1H, | 29.2–29.7 ( | 1.26 (2H, |
| 10 | 131.2 ( | 6.00 (1H, | 32.2 ( | 2.07 (2H, | 29.2–29.7 ( | 1.26 (2H, |
| 11 | 130.7 ( | 5.52 (1H, | 29.3–29.7 ( | 1.26 (2H, | 29.2–29.7 ( | 1.26 (2H, |
| 12 | 32.1 ( | 2.16 (2H, | 29.3–29.7 ( | 1.26 (2H, | 29.2–29.7 ( | 1.26 (2H, |
| 13 | 32.6 ( | 2.04 (2H, | 29.3–29.7 ( | 1.26 (2H, | 29.2–29.7 ( | 1.26 (2H, |
| 14 | 29.4 ( | 1.36 (2H, | 29.3–29.7 ( | 1.26 (2H, | 29.2–29.7 ( | 1.26 (2H, |
| 15 | 29.2 ( | 1.36 (2H, | 29.3–29.7 ( | 1.26 (2H, | 29.2–29.7 ( | 1.26 (2H, |
| 16 | 31.9 ( | 1.26 (2H, | 32.0 ( | 1.26 (2H, | 32.0 ( | 1.26 (2H, |
| 17 | 22.7 ( | 1.26 (2H, | 22.7 ( | 1.26 (2H, | 22.7 ( | 1.26 (2H, |
| 18 | 14.1 ( | 0.87 (3H, | 14.1 ( | 0.88(3H, | 14.1 ( | 0.88(3H, |
| 1′ | 175.1 ( | - | 173.0 ( | - | 173.0 ( | - |
| 2′ | 72.4 ( | 4.12 (1H, | 43.4 ( | a 2.29 (1H, | 43.3 ( | a 2.31 (1H, |
| b 2.41 (1H, | ||||||
| 3′ | 34.8 ( | 2.16 (2H, | 68.9 ( | 4.00 (1H, | 68.9 ( | 4.00 (1H, |
| 4′ | 31.8 ( | 1.26 (2H, | 37.2 ( | a 1.43 (1H, | 37.1 ( | a 1.43 (1H, |
| 5′ | 25.1 ( | 1.62 (2H, | 25.6 ( | a 1.26 (1H, | 25.6 ( | a 1.30 (1H, |
| 6′~13′ | 29.1–29.7 ( | 1.26 (16H, | 29.3–29.7 ( | 1.26 (16H, | 29.2–29.7 ( | 1.26 (16H, |
| 14′ | 29.1–29.7 ( | 1.26 (2H, | 32.0 ( | 1.26 (2H, | 32.0 ( | 1.26 (2H, |
| 15′ | 29.1–29.7 ( | 1.26 (2H, | 22.7 ( | 1.26 (2H, | 22.7 ( | 1.26 (2H, |
| 16′ | 31.9 ( | 1.26 (2H, | 14.1 ( | 0.88 (3H, | 14.1 ( | 0.88 (3H, |
| 17′ | 22.7 ( | 1.26 (2H, | - | - | - | - |
| 18′ | 14.1 ( | 0.87 (3H, | - | - | - | - |
| NH | - | 7.20 (1H, | - | 6.76 (1H, | - | 6.77 (1H, |
a Assignments aided by DEPT, 1H-1H COSY, HSQC, HMBC and NOESY experiments; b overlapped with other signals.
Figure 5Key ESI-MS fragments of compound 3 (a positive fragment ions; b negative fragment ions).
Figure 6Key 1H–1H COSY and HMBC correlations (A), and negative ESI-MS fragments (B) of compound 4.
Figure 7Key negative ESI-MS fragments of compound 5.
Cytotoxicities of compounds 1–5 against three tumor cell lines in vitro (IC50, μM) a.
| Compound | HepG2 | NCI-H460 | SGC7901 |
|---|---|---|---|
|
| 52.1 | >100 | 57.7 |
|
| 47.3 | 84.4 | 52.2 |
|
| 47.8 | 85.1 | 52.9 |
|
| 53.7 | >100 | 57.9 |
|
| 54.6 | >100 | 58.1 |
| Adriamycin b | 0.14 | 0.13 | 0.17 |
a IC50 values are means from three independent experiments in which each compound concentration was tested in three replicate wells; b Adriamycin as positive control.